Analysts Set GeneDx Holdings Corp. (NASDAQ:WGS) Target Price at $133.11

Shares of GeneDx Holdings Corp. (NASDAQ:WGS) have been given a consensus rating of “Moderate Buy” by the eleven research firms that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and seven have issued a buy recommendation on the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $135.8889.

Several research firms have weighed in on WGS. Weiss Ratings reissued a “sell (d)” rating on shares of GeneDx in a research note on Wednesday, October 8th. Canaccord Genuity Group lifted their price objective on GeneDx from $160.00 to $170.00 and gave the stock a “buy” rating in a report on Monday. Wells Fargo & Company set a $155.00 target price on GeneDx and gave the company an “equal weight” rating in a report on Monday, December 15th. Piper Sandler raised their price target on GeneDx from $120.00 to $140.00 and gave the stock an “overweight” rating in a research report on Thursday, September 11th. Finally, BTIG Research lifted their price target on GeneDx from $165.00 to $200.00 and gave the stock a “buy” rating in a research note on Friday, December 12th.

GeneDx Stock Performance

NASDAQ:WGS opened at $140.44 on Monday. The company has a market capitalization of $4.06 billion, a price-to-earnings ratio of 1,560.44 and a beta of 1.99. The business has a 50 day moving average of $141.11 and a 200 day moving average of $116.58. The company has a debt-to-equity ratio of 0.18, a current ratio of 2.71 and a quick ratio of 2.59. GeneDx has a 1-year low of $55.17 and a 1-year high of $170.87.

GeneDx (NASDAQ:WGS) last posted its quarterly earnings results on Tuesday, October 28th. The company reported $0.49 EPS for the quarter, topping the consensus estimate of $0.28 by $0.21. GeneDx had a net margin of 0.52% and a return on equity of 20.22%. The firm had revenue of $116.74 million for the quarter, compared to the consensus estimate of $104.33 million. On average, sell-side analysts predict that GeneDx will post 0.97 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Katherine Stueland sold 10,857 shares of the company’s stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $143.89, for a total transaction of $1,562,213.73. Following the completion of the sale, the chief executive officer directly owned 14,237 shares in the company, valued at $2,048,561.93. This represents a 43.27% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Joshua Ruch sold 38,000 shares of the stock in a transaction on Monday, November 24th. The shares were sold at an average price of $160.37, for a total transaction of $6,094,060.00. Following the sale, the director directly owned 11,941 shares of the company’s stock, valued at $1,914,978.17. The trade was a 76.09% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 60,163 shares of company stock valued at $9,339,792 over the last three months. 29.60% of the stock is owned by company insiders.

Institutional Trading of GeneDx

Several large investors have recently modified their holdings of WGS. T. Rowe Price Investment Management Inc. purchased a new stake in shares of GeneDx in the 1st quarter worth about $44,614,000. ARK Investment Management LLC bought a new position in GeneDx in the third quarter worth about $48,157,000. William Blair Investment Management LLC lifted its holdings in GeneDx by 37.2% in the second quarter. William Blair Investment Management LLC now owns 1,631,402 shares of the company’s stock worth $150,595,000 after buying an additional 442,414 shares during the period. Alliancebernstein L.P. boosted its position in GeneDx by 3,054.5% during the 1st quarter. Alliancebernstein L.P. now owns 436,900 shares of the company’s stock valued at $38,694,000 after acquiring an additional 423,050 shares in the last quarter. Finally, Jennison Associates LLC grew its holdings in shares of GeneDx by 6,163.1% during the 2nd quarter. Jennison Associates LLC now owns 397,896 shares of the company’s stock worth $36,730,000 after acquiring an additional 391,543 shares during the period. 61.72% of the stock is owned by institutional investors.

About GeneDx

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.